Contract facts
FederalELABORATION AND USE OF SYNGENIC PRE-CLINICAL MODELS FOR CANCER DRUG DEVELOPMENT is a federal award for Nih Nci held by Leidos Biomedical Research, Inc. Estimated value $12.1M ($10.3M obligated). Current period of performance ends Sep 15, 2026. Place of performance: FREDERICK MD.
ELABORATION AND USE OF SYNGENIC PRE-CLINICAL MODELS FOR CANCER DRUG DEVELOPMENT
Recompete timing
PublicCurrent PoP ends Sep 15, 2026 (25 days remaining). Agencies typically plan 12–18 months ahead — at 0.8 months out, that window is already open. The buying decision is likely already in motion.
Incumbent footprint
Public recordLeidos Biomedical Research, Inc — $2.1B obligated across 186 awards (firm-wide, all agencies).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75N91021F00017?
75N91021F00017 (Elaboration and USE of syngenic pre-clinical) is a Nih Nci award with a potential value of $12.1M, currently held by Leidos Biomedical Research, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75N91021F00017?
Nih Nci awarded 75N91021F00017 to Leidos Biomedical Research, Inc (potential $12.1M).
Who is the incumbent on 75N91021F00017?
Leidos Biomedical Research, Inc is the incumbent with $2.1B across 186 related awards in SCOUT’s public footprint. The current period of performance ends Sep 15, 2026.
When does Leidos Biomedical Research, Inc’s 75N91021F00017 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 15, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.